Crossmark

Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T

Crossref DOI link: https://doi.org/10.1136/jitc-2021-002931

Published Online: 2021-08-10

Published Print: 2021-08

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Dorff, Tanya https://orcid.org/0000-0001-5990-298X
Hirasawa, Yosuke

Acoba, Jared

Pagano, Ian

Tamura, David

Pal, Sumanta https://orcid.org/0000-0002-1712-0848
Zhang, Minlu

Waitz, Rebecca

Dhal, Abhilash

Haynes, Winston

Shon, John

Scholz, Mark

Furuya, Hideki https://orcid.org/0000-0002-9536-8662
Chan, Owen T M

Huang, Jeffrey

Rosser, Charles https://orcid.org/0000-0002-6052-4223
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03024216 at ClinicalTrials.gov

Documents that mention this clinical trial

Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T
https://doi.org/10.1136/jitc-2021-002931

Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer
https://doi.org/10.1136/jitc-2025-012690
Funding

Funding for this research was provided by:

Dendreon Corp
License Information

License valid from 2021-08-09

Document is current

Any future updates will be listed below